The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.

Abstract:

:Introduction: For over 40 years, ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates across western and central Africa. In December 2013, an unprecedented Ebola virus (EBOV) epidemic began in West Africa and resulted in the largest outbreak to date. The past and current epidemics in West Africa and the Democratic Republic of the Congo has focused attention on the potential vaccine platforms developed over the past 20 years.Areas covered: This review summarizes the extraordinary progress using a variety of vaccination platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, incorporating the primary antigen of EBOV, the glycoprotein. These vaccine constructs have shown varying degrees of protective efficacy in the 'gold-standard' nonhuman primate model for EBOV infections and were immunogenic in human clinical trials.Expert commentary: A number of these vaccine platforms have moved into phase III clinical trials over the past years and with the recent approval of the first EBOV vaccine in the European Union and the USA there is a strong potential to prevent future outbreaks/epidemics of EBOV infections on the scale of the West African epidemic.

journal_name

Expert Rev Vaccines

authors

O'Donnell K,Marzi A

doi

10.1080/14760584.2020.1738225

subject

Has Abstract

pub_date

2020-03-01 00:00:00

pages

267-277

issue

3

eissn

1476-0584

issn

1744-8395

journal_volume

19

pub_type

杂志文章,评审
  • Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics.

    abstract::Vaccine distribution and delivery has become an issue of significant interest, given the threat of a pandemic influenza outbreak and the resulting need for coordinated efforts to distribute and deliver pandemic influenza vaccines into the hands of healthcare workers responsible for administering them. This review prov...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.6.6.981

    authors: Jacobson SH,Sewell EC,Jokela JA

    更新日期:2007-12-01 00:00:00

  • International Dengue Vaccine Communication and Advocacy: Challenges and Way Forward.

    abstract::Dengue vaccine introduction will likely occur soon. However, little has been published on international dengue vaccine communication and advocacy. More effort at the international level is required to review, unify and strategically disseminate dengue vaccine knowledge to endemic countries' decision makers and potenti...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1152187

    authors: Carvalho A,Van Roy R,Andrus J

    更新日期:2016-01-01 00:00:00

  • Efficacy, safety, and formulation issues of the combined vaccines.

    abstract::Introduction: Controlling the preventable infectious diseases is the main goal of vaccination. Among the vaccines, combined vaccines are of great importance for their social, public health, and economic values. It is stated that the combined vaccines are as efficient and safe as the monovalent vaccines. However, a con...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1843434

    authors: Tafreshi SH

    更新日期:2020-10-01 00:00:00

  • Vaccine profile of herpes zoster (HZ/su) subunit vaccine.

    abstract:INTRODUCTION:Herpes zoster (HZ) causes an often severe and painful rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN) and by dissemination in immune-compromised patients. HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age-rel...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1329012

    authors: Cunningham AL,Heineman T

    更新日期:2017-07-01 00:00:00

  • Challenges in estimating influenza vaccine effectiveness.

    abstract::Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1622419

    authors: Ainslie KEC,Haber M,Orenstein WA

    更新日期:2019-06-01 00:00:00

  • Current developments and prospects on human metapneumovirus vaccines.

    abstract:INTRODUCTION:Human metapneumovirus (hMPV) has become one of the major pathogens causing acute respiratory infections (ARI) mainly affecting young children, immunocompromised patients, and the elderly. Currently there are no licensed vaccines against this virus. Areas covered: Since the discovery of hMPV in 2001, many g...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1283223

    authors: Márquez-Escobar VA

    更新日期:2017-05-01 00:00:00

  • Transient expression systems for plant-derived biopharmaceuticals.

    abstract::In the molecular farming area, transient expression approaches for pharmaceutical proteins production, mainly recombinant monoclonal antibodies and vaccines, were developed almost two decades ago and, to date, these systems basically depend on Agrobacterium-mediated delivery and virus expression machinery. We survey h...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.85

    authors: Komarova TV,Baschieri S,Donini M,Marusic C,Benvenuto E,Dorokhov YL

    更新日期:2010-08-01 00:00:00

  • Solid vaccine protection against SIV in rhesus monkeys provides proof-of-concept for further evaluation of a novel HIV vaccine approach in humans.

    abstract::Protection against acquisition of fully heterologous, neutralization-resistant SIV was achieved in rhesus monkeys with adenovirus/poxvirus vector-based vaccines. Protection against acquisition of infection required the inclusion of envelope antigens and correlated with the induction of binding antibodies against the E...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.12.21

    authors: Esparza J

    更新日期:2012-05-01 00:00:00

  • Strategies for inducing effective neutralizing antibody responses against HIV-1.

    abstract::Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine available against HIV-1. Currently, substantial efforts are devoted to the development of vaccines aimed at inducing broadly neutralizing antibodies (bNAbs), which are capable of neutralizing most HIV-1 strains. All bNAb...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2019.1690458

    authors: Del Moral-Sánchez I,Sliepen K

    更新日期:2019-11-01 00:00:00

  • Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review.

    abstract:BACKGROUND:Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. OBJECTIVE:To describe the vaccine efficacy, immunoge...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1150182

    authors: Bakker M,Bunge EM,Marano C,de Ridder M,De Moerlooze L

    更新日期:2016-07-01 00:00:00

  • Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.

    abstract::C-type lectin receptors (CLRs) are a class of pathogen-recognition receptors that are actively investigated in the field of vaccine delivery. Many of their properties have functions linked to the immune system. These receptors are expressed abundantly on antigen-presenting cells and are considered to be the sentinels ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.7.1005

    authors: Tang CK,Sheng KC,Apostolopoulos V,Pietersz GA

    更新日期:2008-09-01 00:00:00

  • Breast cancer vaccines: current research and future prospects.

    abstract::Although the immune system can clearly recognize cancer cells, there is little evidence that it does so to any effective consequence in patients with advanced breast cancer. The possibility of effective control of micrometastatic disease remains but is unproven. The challenge for the clinician is to find ways to enhan...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.1.29

    authors: Cameron DA

    更新日期:2002-06-01 00:00:00

  • Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.

    abstract:BACKGROUND:Viruses from two antigenically distinct influenza B strains have co-circulated since the mid-1980s, yet inactivated trivalent influenza vaccines (TIVs) with either the Victoria or Yamagata lineage could only provide limited protection from influenza B strain. Quadrivalent influenza vaccine (QIV) including bo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14760584.2017.1374181

    authors: Wang SY,Liu SZ,Chu K,Zhao Y,Zhu FC,Hu YM,Meng FY,Li JX,Luo L,Yang JY,Liu P,Yu J

    更新日期:2017-11-01 00:00:00

  • 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.

    abstract::The global burden of disease due to Streptococcus pneumoniae remains high. The licensed 7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar/Prevnar) has successfully reduced invasive disease in the USA, but serotype coverage is incomplete and some evidence suggests that serotype replacement has occurred. Recently...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.09.113

    authors: Prymula R,Schuerman L

    更新日期:2009-11-01 00:00:00

  • Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias.

    abstract::Several studies have identified an association between Pandemrix(TM), an AS03 adjuvanted pandemic influenza A(H1N1) vaccine, and narcolepsy, a rare and under-diagnosed sleep disorder with a median onset-to-diagnosis interval of ten years. This paper reviews potential sources of bias in published studies and aims to pr...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.2016.1164045

    authors: Wijnans L,Dodd C,de Ridder M,Romio S,Weibel D,Overeem S,Lammers GJ,Bonhoeffer J,Black S,Sturkenboom M

    更新日期:2016-05-01 00:00:00

  • Typhoid vaccination: the Asian experience.

    abstract::The WHO has recently issued updated recommendations for the programmatic use of new-generation typhoid vaccines in high-risk areas of countries where typhoid fever is still endemic. Countries have subsequently been instructed to discuss how these recommendations can be implemented and to develop plans for targeted typ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.5.547

    authors: DeRoeck D,Ochiai RL,Yang J,Anh DD,Alag V,Clemens JD

    更新日期:2008-07-01 00:00:00

  • Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.

    abstract::Therapeutic prospects of particulates are increasingly recognized for vaccination purposes. Compared with biologic particulates, such as live or attenuated bacterial vectors and viral vectors, synthetic particulates may be expected to ease the hurdles of quality assurance and validation in vaccine development and prod...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.2.215

    authors: Thiele L,Merkle HP,Walter E

    更新日期:2002-08-01 00:00:00

  • Synthetic biology devices and circuits for RNA-based 'smart vaccines': a propositional review.

    abstract::Nucleic acid vaccines have been gaining attention as an alternative to the standard attenuated pathogen or protein based vaccine. However, an unrealized advantage of using such DNA or RNA based vaccination modalities is the ability to program within these nucleic acids regulatory devices that would provide an immunolo...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.997714

    authors: Andries O,Kitada T,Bodner K,Sanders NN,Weiss R

    更新日期:2015-02-01 00:00:00

  • Molecular mechanisms for enhanced DNA vaccine immunogenicity.

    abstract::In the two decades since their initial discovery, DNA vaccines technologies have come a long way. Unfortunately, when applied to human subjects inadequate immunogenicity is still the biggest challenge for practical DNA vaccine use. Many different strategies have been tested in preclinical models to address this proble...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1124762

    authors: Li L,Petrovsky N

    更新日期:2016-01-01 00:00:00

  • Alternative administration routes and delivery technologies for polio vaccines.

    abstract::Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccin...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1158650

    authors: Kraan H,van der Stel W,Kersten G,Amorij JP

    更新日期:2016-08-01 00:00:00

  • Perspectives on vaccination in adults.

    abstract::In the Second Conference on Controversies in Vaccination in Adults, leading vaccine experts among manufacturers, physicians, microbiologists, virologists, immunologists and public health specialists came together to discuss recent approaches, developments and strategies in vaccination against worldwide pressing epidem...

    journal_title:Expert review of vaccines

    pub_type:

    doi:10.1586/erv.13.44

    authors: Doerr HW

    更新日期:2013-06-01 00:00:00

  • Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations.

    abstract::Introduction Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has quickly spread around the world. Areas covered This review will discuss the available immunologic and clinical evidence to support the benefit of the influenza, pneumococcal, and tuberculosis vaccines...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2020.1825951

    authors: Sultana J,Mazzaglia G,Luxi N,Cancellieri A,Capuano A,Ferrajolo C,de Waure C,Ferlazzo G,Trifirò G

    更新日期:2020-10-01 00:00:00

  • Current challenges in the development of vaccines for pneumonic plague.

    abstract::Inhalation of Yersinia pestis bacilli causes pneumonic plague, a rapidly progressing and exceptionally virulent disease. Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.2.209

    authors: Smiley ST

    更新日期:2008-03-01 00:00:00

  • Vaccine development for syphilis.

    abstract:INTRODUCTION:Syphilis, caused by the spirochete Treponema pallidum subspecies pallidum, continues to be a globally prevalent disease despite remaining susceptible to penicillin treatment. Syphilis vaccine development is a viable preventative approach that will serve to complement public health-oriented syphilis prevent...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1203262

    authors: Lithgow KV,Cameron CE

    更新日期:2017-01-01 00:00:00

  • DNA-launched live-attenuated vaccines for biodefense applications.

    abstract::A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1175943

    authors: Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

    更新日期:2016-09-01 00:00:00

  • Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

    abstract::The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approv...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1099437

    authors: Wei XX,Fong L,Small EJ

    更新日期:2015-01-01 00:00:00

  • Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?

    abstract::Neisseria lactamica is a commensal organism that is closely related to Neisseria meningitidis, the causative agent of meningococcal disease. N. lactamica has many antigens in common with N. meningitidis, but it lacks a polysaccharide capsule and the serosubtyping antigen PorA. Carriage studies have demonstrated that N...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.3.373

    authors: Gorringe AR

    更新日期:2005-06-01 00:00:00

  • Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.

    abstract::The need for an affordable, safe and effective HIV vaccine has never been greater. As the immunogenicity of all the vaccine vectors being evaluated currently in human populations is limited, novel vaccine strategies are needed to stimulate the innate immune system, to generate high levels of neutralizing antibodies an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.6.827

    authors: Joseph J,Saubi N,Pezzat E,Gatell JM

    更新日期:2006-12-01 00:00:00

  • Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

    abstract::Serogroup B Neisseria meningitidis is the leading cause of meningococcal disease in developed countries. There is currently no vaccine offering wide-ranging protection. Development of a serogroup B polysaccharide-based vaccine has been hindered by potential risks of autoantibodies that cross-react with glycosylated ho...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.116

    authors: Bai X,Borrow R

    更新日期:2010-10-01 00:00:00

  • Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120.

    abstract::Evaluation of: Böckl K, Wild J, Bredl S et al. Altering an artificial Gagpolnef polyprotein and mode of Env co-administration affects the immunogenicity of a clade C HIV-1 DNA vaccine. PLoS ONE 7(4), e34723 (2012). SIV vaccination studies in monkeys have revealed that Env-directed antibodies are critical for protect...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/erv.12.102

    authors: van Montfort T,Sanders RW

    更新日期:2012-10-01 00:00:00